Jan
14
2025
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.
“There are no available data from randomized controlled trials in PsA assessing clinical outcomes in patients who have directly switched from [TNF inhibitors] to tofacitinib, and whether they maintain or achieve disease control with an acceptable safety profile,” Dafna D. Gladman, MD, of the department of medicine at the University of Toronto, and colleagues wrote.
“Given
Read More
From Healio.com RHEUMATOLOGY •
•
